Modified FOLFIRINOX failed to improve disease-free survival in stage III disease ...

HER2-positive breast cancer chemotherapy can be safely omitted in about 30% of patients, five-year PHERGain trial data ...

AstraZeneca's experimental antibody-drug conjugate sonesitatug vedotin has doubled overall survival in a late-stage trial for ...

Add Yahoo as a preferred source to see more of our stories on Google. David James, a director at Prostate Cancer Research, says research and treatment advances mean that thousands of men with advanced ...

Diagnostic and surgical approaches to treating the disease are evolving — just as rates are spiking. Learn how the surgical ...

The oncology company said patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma who took a combination of Tevimbra and Ziihera, along with chemotherapy, had an ...

Results from two important studies involving women with advanced endometrial cancer – the fourth most common cancer in women ...

OPTIMA shows Prosigna assay can help many ER-positive, HER2-negative breast cancer patients safely avoid chemotherapy.

In the phase 3 REZILIENT 3 trial, adding zipalertinib to platinum-pemetrexed chemotherapy extended median progression-free ...

Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, ...

A large retrospective database analysis found that intrathecal chemotherapy in leptomeningeal disease was linked to a ...

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.